// App-Quantinova.ai

TPS362 : A prospective, multicenter, dose-escalation, and dose-expansion study evaluating apatinib plus chemotherapy in second-line therapy of patients with postoperatively gastric cancer (ACHIEVE).

Researchers

Presenter

  • Junyi Han

Principal Investigators

  • Tao Pang

  • Zhan Zhang

  • Zhengmao Lu

  • Ping Dong

  • Jianguo Wu

  • Kai Yin

  • Xusheng Chang

  • Tianhang Luo

Medical Centers

  • Dongfang Hospital Affiliated to Tongji University,China

  • Shanghai Renji Hospital, Shanghai, China

  • Xin Hua Hospital to Shanghai Jiao Tong University School of Medicine, Shanghai, China

  • Department of Gastroenterology, The Shanghai Tenth Peoples Hospital of Tongji University, Shanghai, China

Locations

  • China

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Gastroesophageal junction (GEJ) adenocarcinoma

  • Gastric Cancer

Biomarkers

  • Programmed cell death protein 1

  • Programmed death-ligand 1

Drug/Treatment

  • Paclitaxel

  • Docetaxel

  • Apatinib

Outcome

  • N/A

Study Design

  • Multicenteric

  • Prospective

  • Expansion Study

  • Dose Escalation

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved